Aberrant CpG methylation of the TFAP2A gene constitutes a mechanism for loss of TFAP2A expression in human metastatic melanoma

Epigenetics

Volumn 9, Issue 12, 2014, Pages 1641-1647

  Hallberg, Andrea R ^a   Vorrink, Sabine U ^b   Hudachek, Danielle R ^a,b   Cramer Morales, Kimberly ^b   Milhem, Mohammed M ^b   Cornell, Robert A ^b   Domann, Frederick E ^b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

DNA methylation; Epigenetic regulation; Gene expression; Metastatic melanoma

Indexed keywords

ENDOTHELIN RECEPTOR TYPE B; GENOMIC DNA; HERPESVIRUS ENTRY MEDIATOR; MESSENGER RNA; PEPTIDES AND PROTEINS; PLASMID VECTOR; RAC3 PROTEIN; SEMAPHORIN 6A; TRANSCRIPTION FACTOR PAX3; TRANSCRIPTION FACTOR SLUG; UNCLASSIFIED DRUG; TFAP2A PROTEIN, HUMAN; TRANSCRIPTION FACTOR AP 2;

ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; DISEASE ASSESSMENT; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; GENE; GENE SEQUENCE; GENE SILENCING; GENOME; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTATIC MELANOMA; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; TRANSCRIPTION FACTOR ACTIVATING ENHANCER BINDING PROTEIN 2 ALPHA GENE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; MELANOCYTE; MELANOMA; METABOLISM; PATHOLOGY; PHYSIOLOGY;

CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MELANOCYTES; MELANOMA; PROMOTER REGIONS, GENETIC; TRANSCRIPTION FACTOR AP-2;

EID: 84922022544     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/15592294.2014.988062     Document Type: Article

References (21)

1. Nyormoi O, Bar-Eli M. Transcriptional regulation of metastasis-related genes in human melanoma. Clin Exp Metastasis 2003; 20:251-63; PMID:12741683; http:// dx.doi.org/10.1023/A:1022991302172
2. Eckert D, Buhl S, Weber S, Jager R, Schorle H. The AP-2 family of transcription factors. Genome Biol 2005; 6:246; PMID:16420676; http://dx.doi.org/ 10.1186/gb-2005-6-13-246
3. Wenke AK, Bosserhoff AK. Roles of AP-2 transcription factors in the regulation of cartilage and skeletal development. FEBS J 2010; 277:894-902; PMID: 20050923; http://dx.doi.org/10.1111/j.1742-4658. 2009.07509.x
4. Hilger-Eversheim K, Moser M, Schorle H, Buettner R. Regulatory roles of AP-2 transcription factors in vertebrate development, apoptosis and cell-cycle control. Gene 2000; 260:1-12; PMID:11137286; http://dx.doi. org/10.1016/S0378-1119(00)00454-6
5. Huang S, Jean D, Luca M, Tainsky MA, Bar-Eli M. Loss of AP-2 results in downregulation of c-KIT and enhancement of melanoma tumorigenicity and metastasis. EMBO J 1998; 17:4358-69; PMID:9687504; http://dx.doi.org/10.1093/emboj/17.15.4358
6. Tellez C, McCarty M, Ruiz M, Bar-Eli M. Loss of activator protein-2alpha results in overexpression of protease- activated receptor-1 and correlates with the malignant phenotype of human melanoma. J Biol Chem 2003; 278:46632-42; PMID:12975361; http:// dx.doi.org/10.1074/jbc.M309159200
7. Berger AJ, Davis DW, Tellez C, Prieto VG, Gershenwald JE, Johnson MM, Rimm DL, Bar-Eli M. Automated quantitative analysis of activator protein-2alpha subcellular expression in melanoma tissue microarrays correlates with survival prediction. Cancer Res 2005; 65:11185-92; PMID:16322269; http://dx.doi.org/ 10.1158/0008-5472.CAN-05-2300
8. Brewer S, Feng W, Huang J, Sullivan S, Williams T. Wnt1-Cre-mediated deletion of AP-2alpha causes multiple neural crest-related defects. Dev Biol 2004; 267:135-52; PMID:14975722; http://dx.doi.org/ 10.1016/j.ydbio.2003.10.039
9. Knight RD, Javidan Y, Nelson S, Zhang T, Schilling T. Skeletal and pigment cell defects in the lockjaw mutant reveal multiple roles for zebrafish tfap2a in neural crest development. Dev Dyn 2004; 229:87-98; PMID: 14699580; http://dx.doi.org/10.1002/dvdy.10494
10. O'Brien EK, d'Alencon SC, Bonde G, Li W, Schoenebeck J, Allende ML, Gelb BD, Yelon D, Eisen JS, Cornell RA. Transcription factor Ap-2alpha is necessary for development of embryonic melanophores, autonomic neurons and pharyngeal skeleton in zebrafish. Dev Biol 2004; 265:246-61; PMID:14697367; http://dx.doi. org/10.1016/j.ydbio.2003.09.029
11. Van Otterloo E, Li W, Bonde G, Day KM, Hsu MY, Cornell RA. Differentiation of zebrafish melanophores depends on transcription factors AP2 α and AP2 epsilon. PLoS Genet 2010; 6:e1001122; PMID:20862309; http://dx.doi.org/10.1371/journal.pgen.1001122
12. Milunsky JM, Maher TM, Zhao G, Wang Z, Mulliken JB, Chitayat D, Clemens M, Stalker HJ, Bauer M, Burch M, et al. Genotype-phenotype analysis of the branchio-oculo-facial syndrome. Am J Med Genet A 2011; 155A:22-32; PMID:21204207; http://dx.doi. org/10.1002/ajmg.a.33783
13. Douglas DB, Akiyama Y, Carraway H, Belinsky SA, Esteller M, Gabrielson E, Weitzman S, Williams T, Herman JG, Baylin SB. Hypermethylation of a small CpGuanine-rich region correlates with loss of activator protein-2alpha expression during progression of breast cancer. Cancer Res 2004; 64:1611-20; PMID: 14996719; http://dx.doi.org/10.1158/0008-5472. CAN-0318-2
14. Makhov PB, Golovine KV, Kutikov A, Canter DJ, Rybko VA, Roshchin DA, Matveev VB, Uzzo RG, Kolenko VM. Reversal of epigenetic silencing of AP- 2alpha results in increased zinc uptake in DU-145 and LNCaP prostate cancer cells. Carcinogenesis 2011; 32:1773-81; PMID:21940908; http://dx.doi.org/ 10.1093/carcin/bgr212
15. Zeng L, Jarrett C, Brown K, Gillespie KM, Holly JM, Perks CM. Insulin-like growth factor binding protein-3 (IGFBP-3) plays a role in the anti-tumorigenic effects of 5-Aza-2′-deoxycytidine (AZA) in breast cancer cells. Exp Cell Res 2013; 319:2282-95; PMID:23810988; http://dx.doi.org/10.1016/j.yexcr.2013.06.011
16. Penna E, Orso F, Cimino D, Vercellino I, Grassi E, Quaglino E, Turco E, Taverna D. miR-214 coordinates melanoma progression by upregulating ALCAM through TFAP2 and miR-148b downmodulation. Cancer Res 2013; 73:4098-111; PMID:23667173; http://dx.doi.org/10.1158/0008-5472.CAN-12-3686
17. Melnikova VO, Dobroff AS, Zigler M, Villares GJ, Braeuer RR, Wang H, Huang L, Bar-Eli M. CREB inhibits AP-2alpha expression to regulate the malignant phenotype of melanoma. PLoS One 2010; 5:e12452; PMID:20805990; http://dx.doi.org/10.1371/journal. pone.0012452
18. Livingstone E, Zimmer L, Piel S, Schadendorf D. PLX4032: does it keep its promise for metastatic melanoma treatment? Expert Opin Investing Drugs 2010; 19:1439-49; PMID:20942773; http://dx.doi.org/ 10.1517/13543784.2010.527945
19. Solit DB, Rosen N. Resistance to BRAF inhibition in melanomas. N Engl J Med 2011; 364:772-4; PMID:21345109; http://dx.doi.org/10.1056/ NEJMcibr1013704
20. Gollob JA, Sciambi CJ, Peterson BL, Richmond T, Thoreson M, Moran K, Dressman HK, Jelinek J, Issa JP. Phase I trial of sequential low-dose 5-aza-2′-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma. Clin Cancer Res 2006; 12:4619-27; PMID:16899610; http://dx.doi.org/10.1158/1078-0432.CCR-06-0883
21. Li LC, Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics 2002; 18:1427-31; PMID:12424112; http://dx.doi.org/10.1093/ bioinformatics/18.11.1427